MedPath

Phase 3 study of cetirizine dry syrup in children suffering from perennial allergic rhinitis(Open study)

Phase 3
Conditions
Perennial allergic rhinitis
Registration Number
JPRN-jRCT2080220123
Lead Sponsor
GlaxoSmithKline K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Age: 2 to 14, Children with perennial allergic rhinitis, patients eligible for evaluation of nasal symptom, etc.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety,change in the total nasal symptom score, etc.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath